Cytokine-modulating/JJ
activity/NN
of/IN
tepoxalin/NN
,/,
a/DT
new/JJ
potential/JJ
antirheumatic/NN
./.

Tepoxalin/NN
is/VBZ
a/DT
new/JJ
dual/JJ
cyclooxygenase/5-lipoxygenase/NN
anti-inflammatory/JJ
compound/NN
currently/RB
under/IN
clinical/JJ
investigation/NN
./.
=====
It/PRP
has/VBZ
been/VBN
shown/VBN
to/TO
possess/VB
anti-inflammatory/JJ
activity/NN
in/IN
a/DT
variety/NN
of/IN
animal/NN
models/NNS
and/CC
more/RBR
recently/RB
to/TO
inhibit/VB
IL-2/NN
induced/JJ
signal/NN
transduction/NN
./.
=====
The/DT
current/JJ
study/NN
was/VBD
conducted/VBN
to/TO
evaluate/VB
the/DT
cytokine/NN
modulating/NN
activity/NN
of/IN
tepoxalin/NN
and/CC
the/DT
role/NN
of/IN
iron/NN
in/IN
these/DT
effects/NNS
./.
=====
In/IN
human/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NN
)/)
stimulated/VBN
with/IN
OKT3/PMA/NN
,/,
tepoxalin/NN
inhibited/VBD
lymphocyte/NN
proliferation/NN
with/IN
an/DT
IC50/NN
of/IN
6/CD
microM/NN
./.
=====
Additionally/RB
,/,
it/PRP
inhibited/VBD
the/DT
production/NN
of/IN
LTB4/NN
(/(
IC50/NN
=/JJ
0.5/CD
microM/NN
)/)
and/CC
the/DT
cytokines/NNS
IL-2/NN
,/,
IL-6/NN
and/CC
TNF/NN
alpha/NN
(/(
IC50/NN
=/JJ
10-12/CD
microM/NN
)/)
./.
=====
Cytotoxicity/NN
was/VBD
not/RB
demonstrated/VBN
at/IN
these/DT
concentrations/NNS
./.
=====
Add-back/JJ
experiments/NNS
with/IN
either/CC
cytokines/NNS
(/(
IL-2/NN
or/CC
IL-6/NN
)/)
,/,
LTB4/NN
or/CC
conditioned/JJ
media/NNS
failed/VBD
to/TO
restore/VB
the/DT
proliferative/JJ
response/NN
in/IN
the/DT
presence/NN
of/IN
tepoxalin/NN
./.
=====
However/RB
,/,
the/DT
concurrent/JJ
addition/NN
of/IN
iron/NN
(/(
in/IN
the/DT
form/NN
of/IN
ferrous/JJ
or/CC
ferric/JJ
chloride/NN
and/CC
other/JJ
iron/NN
salts/NNS
)/)
reversed/VBD
the/DT
inhibition/NN
of/IN
proliferation/NN
caused/VBN
by/IN
tepoxalin/NN
./.
=====
Tepoxalin/NN
also/RB
inhibits/VBZ
the/DT
activation/NN
of/IN
NF/NN
kappa/NN
B/NN
,/,
a/DT
transcription/NN
factor/NN
which/WDT
acts/VBZ
on/IN
several/JJ
cytokine/NN
genes/NNS
./.
=====
Tepoxalin/NN
's/POS
effect/NN
on/IN
NF/NN
kappa/NN
B/NN
is/VBZ
also/RB
reversed/VBN
by/IN
the/DT
addition/NN
of/IN
iron/NN
salts/NNS
./.
=====
These/DT
data/NNS
suggest/VBP
that/IN
the/DT
action/NN
of/IN
tepoxalin/NN
to/TO
inhibit/VB
proliferation/NN
in/IN
PBMC/NN
may/MD
be/VB
at/IN
least/JJS
in/IN
part/NN
due/JJ
to/TO
its/PRP$
ability/NN
to/TO
reduce/VB
the/DT
amount/NN
of/IN
available/JJ
iron/NN
resulting/VBG
in/IN
decreased/VBN
activation/NN
of/IN
NF/NN
kappa/NN
B/NN
and/CC
subsequent/JJ
inhibition/NN
of/IN
cytokine/NN
production/NN
./.